Skip to content

Addiction: all studies

Page 285 of 857: studies 2,841 to 2,850 of 8,563, newest first. Back to the addiction overview

Research

Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence.

Frontiers in Artificial Intelligence June 4, 2025 Brian M. Ross 1 citation

Psychedelics, such as LSD and psilocybin, disrupt entrenched cognitive patterns by facilitating novel insights and new associations. This paper considers how AI can potentially mimic these psychedelic-induced cognitive disruptions to augment and enhance human creativity. Psychedelics likely enhance creativity by altering brain function, notably the activity of the Default Mode Network, which...

DOI: 10.3389/frai.2025.1589086 (opens in new tab) Full text (opens in new tab) Artificial intelligence: ai Machine learning Computational creativity Creativity enhancement: innovation +10

Neurobehavioral and Molecular Pharmacology of Pharmahuasca ($\textit{N,N}$-dimethyltryptamine (DMT) and Harmine) in Humans – A Combined Neuropharmacological and Brain Imaging Approach

June 4, 2025 Klemens Egger

Over the past decade, research with psychedelics has gained new momentum, leading to a psychedelic renaissance in both basic and clinical research. Among these substances is ayahuasca, an Amazonian plant medicine used for millennia by indigenous people for ritualistic and healing practices, which has recently entered research labs in the Americas and Europe. Preliminary findings indicate its...

DOI: 10.5167/uzh-278132 (opens in new tab) Full text (opens in new tab) Neuroplasticity Psychedelic medicine Mental health treatment Brain imaging

The psychedelic-peptide paradox: a hormetic hypothesis.

Comprehensive Psychoneuroendocrinology June 2, 2025 C. Sue Carter 3 citations

The purpose of this narrative review is to examine the hypothesis that two neuropeptides, vasopressin (VP) and oxytocin (OT) and their receptors have central roles in the behavioral and physiological consequences of psychedelic interventions. Transient consequences of psychedelics can include anxiety and in some cases sickness responses such as nausea and vomiting, which may involve VP and...

Enhancing interoceptive awareness in chronic pain and opioid misuse via mindfulness-oriented recovery enhancement.

Drug and Alcohol Dependence June 2, 2025 Anna Parisi, Lisa Taylor-Swanson, Jennifer L. Stewart et al. 1 citation

Individuals with substance use disorders often report altered interoceptive awareness of internal bodily signals. However, it is unclear whether these alterations also extend to patients with chronic pain who misuse opioids, and whether interventions that enhance interoceptive awareness, such as mindfulness-based therapies, may reduce opioid misuse in this population. At baseline, participants...

DOI: 10.1016/j.drugalcdep.2025.112741 (opens in new tab) Full text (opens in new tab) Interoception Interoceptive awareness Opioid misuse treatment Opioid addiction treatment +14

Consciousness and Mathematics: A Number Theoretic Approach to Modelling Reality

Journal of Physics, Conference Series June 1, 2025 Mahendra Samarawickrama

This research analyses the fundamentals of numbers for interpreting consciousness and reality. Complementing Gödel’s incompleteness theorems, we adopted number theory to explore non-referential and self-referential constructs. By examining consciousness, causation, and fundamental mathematical models of reality, we analysed stages of cognition and the emergence of self-referencing as a...

Consciousness and Matter: Mind, Brain, and Cosmos in the Dialogue Between Science and Theology

Perspectives on Science and Christian Faith June 1, 2025

CONSCIOUSNESS AND MATTER: Mind, Brain, and Cosmos in the Dialogue Between Science and Theology by Kirill Kopeikin and Alexei V. Nesteruk, eds. Pickwick, 2024. 262 pages. Paperback; $35.00. ISBN: 9781666776997. *This is a notable interdisciplinary volume that tackles the complex relationship between the mind and body, exploring it within the broader context of dialogue between science and...

A Case of Depersonalization-Derealization Disorder

BJPsych Open June 1, 2025 Emeka Onochie, Joseph Verghese

Aims: Background: Depersonalization-derealization disorder (DPDR), classified under ICD–11 code 6B66, involves persistent or recurrent experiences of depersonalization, derealization, or both. Depersonalization refers to a sense of detachment from one’s thoughts, emotions, or body, whereas derealization involves perceiving the external world as unreal or distorted. These symptoms cause...

Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?

Toxicology Reports June 1, 2025 Eva Gil-Martins, Daniel José Barbosa, Fernanda Borges et al. 2 citations

Drug use represents a prevalent and multifaceted societal problem, with profound implications for public health, social welfare, and economic stability. To circumvent strict international drug control regulations, there is a growing trend in the development and market introduction of novel psychoactive substances (NPS), encompassing a wide range of compounds with psychoactive properties. This...

DOI: 10.1016/j.toxrep.2025.101890 (opens in new tab) Full text (opens in new tab) Abuse potential New psychoactive substances Psychedelic phenethylamines

Advanced and long-term meditation and the autonomic nervous system: A review and synthesis.

Neuroscience & Biobehavioral Reviews June 1, 2025 Idil Sezer, Matthew D. Sacchet 14 citations

Meditation has become prominent in both clinical and non-clinical applications for its effects on psychological and physical well-being. Long-term meditators, who have dedicated extensive time to their practice, present a unique opportunity to explore the effects of prolonged meditation training on the autonomic nervous system. Research has reported concomitant activation of both sympathetic...

DOI: 10.1016/j.neubiorev.2025.106141 (opens in new tab) Full text (opens in new tab) Advanced meditation Autonomic nervous system Brain-body interactions Cardiac resonance +2

Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study.

Neuropsychopharmacology June 1, 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason et al. 8 citations

3-Methylmethcathinone (3-MMC) is a designer drug that belongs to the group of synthetic cathinones. The compound has been scheduled in many jurisdictions because of public health concerns associated with excessive use. To date, there are no clinical studies that have evaluated the risk profile of 3-MMC in the recreational range of low to moderate doses. The current, first-in-human study (N =...